Skip to main content

Hyaluronic Acid Filler — Penile Girth Augmentation

Hyaluronic acid (HA) filler injection is an emerging, minimally invasive office-based procedure for penile girth enhancement. It is the most commonly studied injectable filler for this indication and is considered the best-tolerated non-surgical girth-enhancement option, with a defining clinical advantage of reversibility with hyaluronidase.[1][2] No standardized clinical guidelines exist; the procedure remains largely off-label. For positioning vs other male cosmetic options see Cosmetic Genital Surgery — Male.

Society positioning

The SMSNA 2024 Position Statement characterizes most non-surgical and surgical penile-augmentation procedures as investigational, with low-quality evidence and a strong recommendation that psychosexual counseling precede any intervention. HA fillers are FDA-approved for facial soft-tissue augmentation only — penile use is off-label.[1][2]

Patient population and indications​

The primary indication is small penis syndrome (SPS) / penile dysmorphophobia (PDD) — a form of body-image / anxiety disorder in which men with objectively normal penile dimensions are dissatisfied with their size. Distinct from true micropenis (stretched penile length < 2.5 SD below mean).[3] Most men seeking penile augmentation have penile dimensions within the normal range.[4] See Small Penis Syndrome / PDD for the full clinical context.

Key pre-treatment considerations:

  • Psychosexual counseling first. Many patients can be reassured without treatment.[5]
  • Psychosocial improvement does not correlate with penile-size change — the psychological benefit appears partly independent of the physical outcome.[6]
  • Patients should understand the temporary nature of HA fillers and the need for repeat treatments.[7]

Mechanism and material properties​

HA is a naturally occurring glycosaminoglycan in the extracellular matrix. When injected as a cross-linked gel, it produces volume augmentation through hydrophilic expansion — each molecule binds up to 1,000× its weight in water. Advantages over other injectable materials[4][8][9]:

  • Biocompatibility — naturally occurring substance with minimal immunogenicity.
  • Reversibility — dissolved with hyaluronidase if complications or undesired results.
  • Predictable degradation — gradually resorbed over months, allowing controlled retreatment.

Injection technique​

No universally standardized protocol exists. Common elements[10][1][11]:

  • Products: Restylane Sub-Q (Q-med), Macrolane VRF 30, and various high-viscosity, large-particle HA gels for deep-tissue augmentation.
  • Volume: mean 20–40 mL across studies.[1]
  • Plane: dartos / subcutaneous fascia of the penile shaft, between the skin and Buck's fascia, avoiding the neurovascular bundle and corpora cavernosa.[11]
  • Anesthesia: local penile block or topical anesthetic; ambulatory / office setting.[12]

Described techniques​

TechniqueApproachKey feature
"Back & Forth" (Kwak 2011)21 G cannula, fascial layer; manual roller homogenizationUniform shaft distribution[11]
Emicircumferential (Sito 2013)Semicircular pattern (ventral or dorsal) rather than circumferentialReduced vascular-compromise risk; favorable vs lipofilling (no complications HA arm vs 8 granulomas with fat)[7]
Multi-point injection (Boiko 2023)Multiple shaft points + manual moldingUniform distribution; large-cohort outcome data[6]

Efficacy​

StudynVolumeFollow-upFlaccid girth gainErect girth gainSatisfaction
Kwak 2011 J Sex Med[11]5020.6 mL18 mo+3.93 cm at 1 mo / +3.78 at 18 moNR3.34 / 4 patient; 3.38 / 4 partner
Yang 2019 RCT J Sex Med[9]36 (HA)NR48 wk+1.70 cmNRmaintained ≤ 48 wk
Yang 2020 24-wk RCT J Sex Med[3]39 (HA)NR24 wk+2.1 cmNRVAS appearance +1.8; sex life +1.0
Yang 2020 18-mo RCT J Clin Med[13]33 (HA)NR18 mosignificant (p < 0.001)NRsustained
Zhang 2022 Asian J Androl[5]3821.5 mL12 mo+3.41 cm at 1 mo / +2.44 at 12 mo+1.32 / +0.80 cmIMGI +46.2; IIEF +7.6
Quan 2021 Asian J Androl[10]230NR6 mo+2.66 cm at 1 mo / +1.80 at 6 moNRnot formally assessed
Boiko 2023 Aesthet Surg J[6]132NRNR+1.7 cm midshaft / +1.5 cm glansNRsexual satisfaction +17.9; confidence +12.2
Sito 2013 (HA + lipofilling)[7]83NRNR+3.2–4.5 cm circumferencedecrement during erection87% "very satisfied"

Key efficacy patterns​

  • Greatest at 1 month, attenuating over 6–18 months due to HA resorption — but remain statistically significant at all measured time points.[10][9][13]
  • Flaccid girth gains > erect girth gains — at 12 months, erect girth gain was only +0.80 cm vs +2.44 cm flaccid.[5]
  • Modest flaccid length increase (+1.65–2.55 cm) — likely from added volume pushing penile skin forward, not a primary effect.[5][7]
  • Erectile-function improvement — IIEF +7.6 (p < 0.05) post-injection.[5]
  • Psychological benefits (improved genital self-image, reduced inadequacy beliefs, improved confidence) persist even as physical gains attenuate.[5][3]

HA vs polylactic acid (PLA) fillers​

The most robust comparative data come from a series of multicenter RCTs by Yang et al.[3][9][13]:

  • At 4 weeks, HA produced significantly greater girth than PLA (p < 0.05).
  • At 48 weeks and 18 months, both groups maintained statistically significant gains; non-inferiority demonstrated for PLA vs HA.
  • HA: faster onset, reversible.
  • PLA: slower-onset collagen-stimulating mechanism, longer-lasting, not reversible.

HA vs other penile augmentation methods​

MethodGirth gainDurationReversibleComplicationsKey limitation
HA filler+1.5–3.9 cm6–18 mo (temporary)Yes — hyaluronidase4.3–14.3% (mild)Repeat treatments; attenuation
Lipofilling (autologous fat)+3.2–4.5 cmunpredictable resorptionNoGranuloma, fat necrosis (9.6–10.8%)Unpredictable resorption; donor-site morbidity
Surgical grafts (dermal / AlloDerm)significantPermanentNoSkin necrosis, infection, reoperation (53.3% of studies)Negative impact on penile length; higher morbidity
Silicone implants (Penuma)significantPermanentSurgical removalInfection, erosion, seroma, necrosis; removal up to 10%Risk of severe deformity

A narrative review concluded HA filler injections are better tolerated than other penile-augmentation methods, though follow-up periods remain short. Surgical grafts improved girth and satisfaction but had a negative impact on penile length and higher complication rates. Silicone implants carried risks of infection, erosion, and necrosis with removal rates up to 10%.[4]

Safety and complications​

HA filler injection for penile augmentation is consistently reported as safe with low complication rates.[5][3][9][10][6]

  • Overall complication rate 4.3% in the largest series (Quan 2021, n = 230) over 6 months.[10]

Reported complications[10][4][8]:

  • Subcutaneous bleeding / bruising — most common; self-limiting.
  • Subcutaneous nodules — palpable lumps from uneven distribution or focal HA accumulation.
  • Penile edema — transient; more common with redundant prepuce.
  • Gel migration — displacement from injection site; associated with redundant prepuce.
  • Infection — rare; managed with antibiotics.
  • Contour irregularities / asymmetry — corrected with hyaluronidase or additional filler.[12][8]
  • No systemic or local allergic reactions in any major series.[10]
  • No serious adverse events (vascular compromise, necrosis, ED) in prospective HA-augmentation studies.[3][9][13]
Critical: distinguish HA from unapproved oil-based injectables

HA fillers must be differentiated from unapproved oil-based substances (silicone oil, paraffin, mineral oil, Vaseline) injected in non-medical settings — see Non-Autologous Injectables — DO NOT USE for the full per-substance breakdown. These cause sclerosing lipogranuloma ("paraffinoma" / "siliconoma") requiring complex tissue excision and skin transplantation. Patients with prior history of these injections are not candidates for HA filler over the same area.[4]

Reversibility with hyaluronidase​

The defining advantage of HA over other injectable materials.[8][14]

  • Moon 2025 Int J Impot Res case series specifically addressing penile HA management — hyaluronidase effective for correcting asymmetries, managing adverse effects, and preparing the site for reinjection after penile girth enhancement.[8]
  • Hyaluronidase is FDA-approved as an adjuvant for subcutaneous fluid administration and drug dispersion; filler-dissolution use is off-label.[15]
  • Alam 2018 JAMA Dermatol RCT — dose-dependent response for HA dissolution; different HA products show varying sensitivity to degradation.[14]
  • Considered safe with no major adverse reactions in dermatologic literature; rare hypersensitivity reactions to hyaluronidase itself theoretically possible.[16][17]

Durability and retreatment​

HA filler augmentation is inherently temporary — both a limitation and a safety feature.

  • Peak girth gains at 1 month.
  • Gradual attenuation over 6–18 months due to enzymatic degradation and mechanical forces.
  • At 12 months, flaccid girth gains retain ~ 70–75% of 1-month peak (e.g., +3.41 → +2.44 cm).[5]
  • At 18 months, significant augmentation persists in RCT data (p < 0.001).[13]
  • One Restylane Sub-Q series reported maintenance at 18 months with minimal attenuation (11.41 → 11.26 cm).[11]
  • Repeat treatments are necessary to maintain results, with cumulative cost.[7]
  • Variability in durability reflects HA-product cross-linking density, injection volume, plane, and individual patient metabolism.

Correction of secondary deformities​

HA fillers have also been used to correct secondary contour deformities of the penis after prior augmentation procedures (e.g., after excision of non-absorbable substances). Yordanov 2021 case series of 5 patients — HA effective for residual irregularities, with excellent tissue integration even in fibrosis from prior surgeries; high satisfaction, no complications at 9-mo follow-up.[12]

Limitations of current evidence​

  • No standardized injection protocol — volumes / products / techniques / planes vary across studies.[10][1]
  • Overall low quality of evidence — vast majority of studies (89.7%) are not RCTs.[2]
  • Short follow-up periods — most studies report 6–18 mo; very long-term data lacking.[4]
  • High dropout rates — up to 43.1% in some RCTs.[9]
  • Publication bias — adverse events likely under-reported.[2]
  • Lack of standardized outcome measures — different studies use different satisfaction and girth-measurement instruments.
  • No head-to-head RCTs vs surgical girth enhancement.

Where HA filler fits​

  • First-line injectable for cosmetic penile girth enhancement among men with normal penile dimensions and persistent dissatisfaction (PDD / SPS), after psychosexual counseling and reassurance attempts.
  • Best risk-benefit profile of all injectable options — reversible, well-tolerated, low complication rate.
  • Repeat treatments are required to maintain results — counsel patients on cumulative cost and the temporal pattern of attenuation.
  • HA is not a length-enhancement intervention — for length see Penile Traction Therapy.
  • Surgical alternatives (Penuma silicone sleeve, dermal grafts) are permanent but carry markedly higher complication rates and the strong negative-impact-on-length signal.
  • Multidisciplinary approach is recommended — psychological assessment, realistic expectations, informed consent regarding the temporary nature and complications.[4]

See also​

Cosmetic Genital Surgery — Male · Small Penis Syndrome / PDD · Penile Traction Therapy · Vacuum Erection Device · Penile Implants

References​

1. Salloum A, Bazzi N, Haber R. Nonsurgical methods for penile augmentation: a systematic review. Dermatol Surg. 2021;47(3):e81-e85. doi:10.1097/DSS.0000000000002816

2. Manfredi C, Romero Otero J, Djinovic R. Penile girth enhancement procedures for aesthetic purposes. Int J Impot Res. 2022;34(4):337-342. doi:10.1038/s41443-021-00459-y

3. Yang DY, Jeong HC, Ahn ST, et al. A comparison between hyaluronic acid and polylactic acid filler injections for temporary penile augmentation in patients with small penis syndrome: a multicenter, patient/evaluator-blind, comparative, randomized trial. J Sex Med. 2020;17(1):133-141. doi:10.1016/j.jsxm.2019.10.006

4. Ramazan M, Øbro LF, Wiborg MH, et al. Complications of penile augmentation: a narrative review of injectables, implants, and surgical grafts. Int J Impot Res. 2026;38(3):238-246. doi:10.1038/s41443-025-01190-8

5. Zhang CL, Quan Y, Li H, et al. Penile augmentation with injectable hyaluronic acid gel: an alternative choice for small penis syndrome. Asian J Androl. 2022;24(6):601-606. doi:10.4103/aja20223

6. Boiko MI, Notsek MS, Boiko OM. The efficacy of injection penile girth enhancement as an option for small penis syndrome management. Aesthet Surg J. 2023;44(1):84-91. doi:10.1093/asj/sjad152

7. Sito G, Marlino S, Santorelli A. Use of Macrolane VRF 30 in emicircumferential penis enlargement. Aesthet Surg J. 2013;33(2):258-264. doi:10.1177/1090820X12472337

8. Moon DG, Cho SB, Ahn ST. Managing residual volumes in penile girth enhancement with hyaluronic acid fillers: a case series and literature review. Int J Impot Res. 2025. doi:10.1038/s41443-025-01182-8

9. Yang DY, Ko K, Lee SH, Lee WK. A comparison of the efficacy and safety between hyaluronic acid and polylactic acid filler injection in penile augmentation: a multicenter, patient/evaluator-blinded, randomized trial. J Sex Med. 2019;16(4):577-585. doi:10.1016/j.jsxm.2019.01.310

10. Quan Y, Gao ZR, Dai X, et al. Complications and management of penile augmentation with hyaluronic acid injection. Asian J Androl. 2021;23(4):392-395. doi:10.4103/aja.aja_78_20

11. Kwak TI, Oh M, Kim JJ, Moon DG. The effects of penile girth enhancement using injectable hyaluronic acid gel, a filler. J Sex Med. 2011;8(12):3407-3413. doi:10.1111/j.1743-6109.2010.01748.x

12. Yordanov YP. Nonsurgical correction of secondary contour deformities of the penile girth. Aesthet Surg J. 2021;41(8):944-949. doi:10.1093/asj/sjab089

13. Yang DY, Jeong HC, Ko K, et al. Comparison of clinical outcomes between hyaluronic and polylactic acid filler injections for penile augmentation in men reporting a small penis: a multicenter, patient-blinded/evaluator-blinded, non-inferiority, randomized comparative trial with 18 months of follow-up. J Clin Med. 2020;9(4):E1024. doi:10.3390/jcm9041024

14. Alam M, Hughart R, Geisler A, et al. Effectiveness of low doses of hyaluronidase to remove hyaluronic acid filler nodules: a randomized clinical trial. JAMA Dermatol. 2018;154(7):765-772. doi:10.1001/jamadermatol.2018.0515

15. US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.

16. Landau M. Hyaluronidase caveats in treating filler complications. Dermatol Surg. 2015;41 Suppl 1:S347-S353. doi:10.1097/DSS.0000000000000555

17. Sharma DSC, Lahiri MA. Use of hyaluronidase in plastic surgery: a review. J Plast Reconstr Aesthet Surg. 2021;74(7):1610-1614. doi:10.1016/j.bjps.2021.03.125